Annual EBIT
-$128.56 M
-$43.78 M-51.64%
31 December 2023
Summary:
Spyre Therapeutics annual earnings before interest & taxes is currently -$128.56 million, with the most recent change of -$43.78 million (-51.64%) on 31 December 2023. During the last 3 years, it has fallen by -$62.91 million (-95.84%). SYRE annual EBIT is now -1343.89% below its all-time high of -$8.88 million.SYRE EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$55.39 M
-$11.24 M-25.47%
30 September 2024
Summary:
Spyre Therapeutics quarterly earnings before interest & taxes is currently -$55.39 million, with the most recent change of -$11.24 million (-25.47%) on 30 September 2024. Over the past year, it has dropped by -$22.15 million (-66.62%). SYRE quarterly EBIT is now -6363.48% below its all-time high of -$857.00 thousand, reached on 01 March 2014.SYRE Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$195.07 M
-$22.15 M-12.81%
30 September 2024
Summary:
Spyre Therapeutics TTM earnings before interest & taxes is currently -$195.07 million, with the most recent change of -$22.15 million (-12.81%) on 30 September 2024. Over the past year, it has dropped by -$95.09 million (-95.12%). SYRE TTM EBIT is now -22661.61% below its all-time high of -$857.00 thousand, reached on 01 March 2014.SYRE TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SYRE EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -51.6% | -66.6% | -95.1% |
| 3 y3 years | -95.8% | -171.0% | -197.1% |
| 5 y5 years | -60.0% | -152.8% | -142.8% |
SYRE EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -95.8% | at low | -195.3% | at low | -197.1% | at low |
| 5 y | 5 years | -95.8% | at low | -726.1% | at low | -197.1% | at low |
| alltime | all time | -1343.9% | at low | -6363.5% | at low | <-9999.0% | at low |
Spyre Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$55.39 M(+25.5%) | -$195.07 M(+12.8%) |
| June 2024 | - | -$44.15 M(-7.6%) | -$172.92 M(+9.8%) |
| Mar 2024 | - | -$47.77 M(+0.0%) | -$157.53 M(+22.5%) |
| Dec 2023 | -$128.56 M(+51.6%) | -$47.75 M(+43.6%) | -$128.56 M(+28.6%) |
| Sept 2023 | - | -$33.24 M(+15.6%) | -$99.97 M(+16.9%) |
| June 2023 | - | -$28.76 M(+52.9%) | -$85.48 M(+8.0%) |
| Mar 2023 | - | -$18.81 M(-1.9%) | -$79.15 M(-6.6%) |
| Dec 2022 | -$84.78 M(+29.1%) | - | - |
| Dec 2022 | - | -$19.16 M(+2.2%) | -$84.78 M(-1.5%) |
| Sept 2022 | - | -$18.75 M(-16.4%) | -$86.06 M(-1.8%) |
| June 2022 | - | -$22.42 M(-8.3%) | -$87.60 M(+21.9%) |
| Mar 2022 | - | -$24.44 M(+19.6%) | -$71.88 M(+9.5%) |
| Dec 2021 | -$65.65 M(-19.4%) | -$20.44 M(+0.7%) | -$65.65 M(-3.4%) |
| Sept 2021 | - | -$20.29 M(+202.7%) | -$67.98 M(+3.3%) |
| June 2021 | - | -$6.71 M(-63.2%) | -$65.81 M(-18.4%) |
| Mar 2021 | - | -$18.21 M(-20.1%) | -$80.67 M(-1.0%) |
| Dec 2020 | -$81.48 M(+1.4%) | -$22.78 M(+25.7%) | -$81.48 M(+1.1%) |
| Sept 2020 | - | -$18.12 M(-15.9%) | -$80.61 M(-4.8%) |
| June 2020 | - | -$21.56 M(+13.3%) | -$84.64 M(+3.6%) |
| Mar 2020 | - | -$19.02 M(-13.2%) | -$81.70 M(+1.7%) |
| Dec 2019 | -$80.33 M | -$21.91 M(-1.1%) | -$80.33 M(+9.0%) |
| Sept 2019 | - | -$22.15 M(+18.9%) | -$73.73 M(+15.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2019 | - | -$18.62 M(+5.5%) | -$63.83 M(+16.3%) |
| Mar 2019 | - | -$17.66 M(+15.4%) | -$54.88 M(+20.7%) |
| Dec 2018 | -$45.46 M(+64.3%) | -$15.30 M(+25.0%) | -$45.46 M(+23.6%) |
| Sept 2018 | - | -$12.24 M(+26.6%) | -$36.78 M(+13.0%) |
| June 2018 | - | -$9.67 M(+17.3%) | -$32.54 M(+10.0%) |
| Mar 2018 | - | -$8.24 M(+24.4%) | -$29.59 M(+6.9%) |
| Dec 2017 | -$27.68 M(+26.3%) | -$6.63 M(-17.2%) | -$27.68 M(+4.1%) |
| Sept 2017 | - | -$8.00 M(+19.0%) | -$26.59 M(+6.8%) |
| June 2017 | - | -$6.72 M(+6.1%) | -$24.89 M(+5.2%) |
| Mar 2017 | - | -$6.33 M(+14.2%) | -$23.67 M(+8.1%) |
| Dec 2016 | -$21.91 M(+93.6%) | -$5.54 M(-12.0%) | -$21.91 M(+7.6%) |
| Sept 2016 | - | -$6.30 M(+14.7%) | -$20.36 M(+16.5%) |
| June 2016 | - | -$5.50 M(+20.3%) | -$17.48 M(+30.3%) |
| Mar 2016 | - | -$4.57 M(+14.3%) | -$13.41 M(+18.5%) |
| Dec 2015 | -$11.31 M(+27.1%) | -$4.00 M(+17.0%) | -$11.31 M(+7.8%) |
| Sept 2015 | - | -$3.42 M(+138.6%) | -$10.50 M(+2.7%) |
| June 2015 | - | -$1.43 M(-42.0%) | -$10.22 M(-2.8%) |
| Mar 2015 | - | -$2.47 M(-22.4%) | -$10.52 M(+18.1%) |
| Dec 2014 | -$8.90 M | -$3.18 M(+1.3%) | -$8.90 M(+55.6%) |
| Sept 2014 | - | -$3.14 M(+81.9%) | -$5.72 M(+121.6%) |
| June 2014 | - | -$1.73 M(+101.4%) | -$2.58 M(+201.4%) |
| Mar 2014 | - | -$857.00 K | -$857.00 K |
FAQ
- What is Spyre Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Spyre Therapeutics?
- What is Spyre Therapeutics annual EBIT year-on-year change?
- What is Spyre Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Spyre Therapeutics?
- What is Spyre Therapeutics quarterly EBIT year-on-year change?
- What is Spyre Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Spyre Therapeutics?
- What is Spyre Therapeutics TTM EBIT year-on-year change?
What is Spyre Therapeutics annual earnings before interest & taxes?
The current annual EBIT of SYRE is -$128.56 M
What is the all time high annual EBIT for Spyre Therapeutics?
Spyre Therapeutics all-time high annual earnings before interest & taxes is -$8.88 M
What is Spyre Therapeutics annual EBIT year-on-year change?
Over the past year, SYRE annual earnings before interest & taxes has changed by -$43.78 M (-51.64%)
What is Spyre Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of SYRE is -$55.39 M
What is the all time high quarterly EBIT for Spyre Therapeutics?
Spyre Therapeutics all-time high quarterly earnings before interest & taxes is -$857.00 K
What is Spyre Therapeutics quarterly EBIT year-on-year change?
Over the past year, SYRE quarterly earnings before interest & taxes has changed by -$22.15 M (-66.62%)
What is Spyre Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of SYRE is -$195.07 M
What is the all time high TTM EBIT for Spyre Therapeutics?
Spyre Therapeutics all-time high TTM earnings before interest & taxes is -$857.00 K
What is Spyre Therapeutics TTM EBIT year-on-year change?
Over the past year, SYRE TTM earnings before interest & taxes has changed by -$95.09 M (-95.12%)